ONCY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Oncolytics Biotech Inc (ONCY) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive insider buying trends and promising developments in the oncology market, the company's financial performance remains weak, with no revenue growth and negative net income. The technical indicators are neutral, and there are no strong proprietary trading signals or significant catalysts to justify immediate action.
The MACD histogram is positive at 0.0213 and contracting, suggesting mild bullish momentum. RSI is neutral at 57.895, indicating no overbought or oversold conditions. Moving averages are converging, showing no clear trend. Key support and resistance levels are Pivot: 1.011, R1: 1.152, S1: 0.869, R2: 1.24, S2: 0.781.
Insider buying has increased by 134.84% over the last month.
The global oncology market is projected to grow significantly, with cancer drug revenues expected to reach $335.2 billion by
Oncolytics Biotech is advancing registrational programs in anal and colorectal cancer and plans to meet with the FDA in mid-April 2026 for approval.
Strengthened leadership with new strategic appointments.
The company has no revenue growth and remains unprofitable, with a net income of -$14.4 million in Q3
EPS remains negative at -0.14 despite a slight improvement.
No significant hedge fund activity or trading trends over the last quarter.
In Q3 2025, revenue remained at $0 with no YoY growth. Net income improved by 50.90% YoY but is still negative at -$14.4 million. EPS improved by 16.67% YoY to -0.14. Gross margin remains at 0 with no growth.
No data available for analyst ratings or price target changes.
